Piperacillin-Tazobactam (Polymicrobial Open Fracture Infections)
Brand names: Tazocin
Piperacillin-tazobactam is a broad-spectrum intravenous combination of a ureidopenicillin and a beta-lactamase inhibitor, used for polymicrobial infections complicating open (compound) fractures.
The product information we hold does not support a dose for this page's specific use, route or population, so none is shown. Follow your local or national guideline, and confirm against the product SmPC.
The licensed dosing — for the medicine's licensed uses, which may differ from this page's — is on Piperacillin-Tazobactam.
Clinical monograph
How it works
Piperacillin inhibits bacterial cell-wall synthesis via penicillin-binding proteins, while tazobactam inhibits many beta-lactamases to protect piperacillin, giving broad Gram-positive, Gram-negative and anaerobic cover.
Prescribing in practice
- Contraindicated in patients with severe penicillin or beta-lactam allergy, as serious cross-reactive hypersensitivity can occur.
- Adjust the dose in renal impairment and use under microbiology and stewardship guidance with timely de-escalation once cultures return.
- Concurrent use can raise the risk of acute kidney injury when combined with vancomycin, so monitor renal function closely.
Monitoring
Monitor renal function, full blood count and inflammatory markers during therapy, especially on prolonged courses.
Counselling the patient
- Report any rash, swelling or breathing difficulty as a possible allergic reaction.
- New or persistent diarrhoea should be reported as a possible bowel infection.
- The antibiotic is being targeted once swab and culture results are available.
Evidence & guidelines
Broad-spectrum cover for open-fracture infection is supported by UK orthopaedic-trauma and antimicrobial guidance, with prompt culture-guided de-escalation.
Reference: MERINO Trial (NEJM 2018); BOAST Open Fracture Guidelines 2017; WHO AWaRe Classification; SPC Tazocin; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- SMART2 Risk Score for Recurrent Vascular Events · Cardiovascular Risk
- MAGGIC Heart Failure Risk Score · Heart Failure
- Long QT Syndrome (Schwartz Score) · Channelopathy / Sudden Cardiac Death
- PCSK9 Inhibitor Eligibility (NICE TA393 / TA394) · Lipid Management
- Ottawa Ankle Rules · Trauma
- Ottawa Knee Rule · Trauma
- Hip Fracture Management · NICE CG124 / BOA 2020
- Distal Radius Fracture · BOA / NICE
- Ankle Fracture Management · BOA / Lauge-Hansen classification
- Metastatic Spinal Cord Compression · NICE CG75 2020
- Open Fracture Management · BOA/BAPRAS 2017
- OrthoPath: Upper Limb ED Triage · OrthoPath ED Tool — ReviseMRCEM.com